<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36117390</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4598</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Muscle &amp; nerve</Title><ISOAbbreviation>Muscle Nerve</ISOAbbreviation></Journal><ArticleTitle>Early initiation of riluzole may improve absolute survival in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>702</StartPage><EndPage>708</EndPage><MedlinePgn>702-708</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mus.27724</ELocationID><Abstract><AbstractText Label="INTRODUCTION/AIMS">Riluzole improves survival in amyotrophic lateral sclerosis (ALS), but optimal time and duration of treatment are unknown. The aim of this study was to examine if timing of riluzole initiation and duration of treatment modified its effect on survival.</AbstractText><AbstractText Label="METHODS">Patients from the PRO-ACT dataset with information on ALS Functional Rating Scale, time from onset to enrollment (TFOE), and riluzole use were selected for analysis. Survival from enrollment was the outcome. Multivariable Cox proportional hazard models were examined for interactions between riluzole and TFOE. Inverse probability of treatment weighting (IPTW) was used to assess average treatment effect.</AbstractText><AbstractText Label="RESULTS">Of 4778 patients, 3446 (72.1%) had received riluzole. In unadjusted analyses, riluzole improved median survival significantly (22.6 vs. 20.2&#xa0;months, log-rank p&#x2009;&lt;&#x2009;0.001). In multivariable analyses, no significant interaction between TFOE and riluzole was found. Riluzole effect was uniform during follow-up. By IPTW, estimated riluzole hazard ratio was 0.798 (95% confidence interval 0.686-0.927). Delaying riluzole initiation by 1&#xa0;y (6 to 18&#x2009;months from onset) may translate to reducing median survival from onset by 1.9&#xa0;months (40.1 to 38.2&#xa0;months).</AbstractText><AbstractText Label="DISCUSSION">Riluzole appears to reduce risk of death uniformly, regardless of time from onset to treatment, and duration of treatment. Earlier treatment with riluzole may be associated with greater absolute survival gain from onset. Early diagnosis of ALS will facilitate early treatment and is expected to improve survival.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Muscle &amp; Nerve published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thakore</LastName><ForeName>Nimish J</ForeName><Initials>NJ</Initials><Identifier Source="ORCID">0000-0003-3418-3362</Identifier><AffiliationInfo><Affiliation>Neuromuscular Center, Department of Neurology, Cleveland Clinic, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lapin</LastName><ForeName>Brittany R</ForeName><Initials>BR</Initials><AffiliationInfo><Affiliation>Neurological Institute Center for Outcomes Research and Evaluation (NICORE) and Lerner Research Institute Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitsumoto</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Division of Neuromuscular Medicine, Columbia University Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pooled Resource Open-Access Als Clinical Trials Consortium</LastName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Muscle Nerve</MedlineTA><NlmUniqueID>7803146</NlmUniqueID><ISSNLinking>0148-639X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>7LJ087RS6F</RegistryNumber><NameOfSubstance UI="D019782">Riluzole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019782" MajorTopicYN="N">Riluzole</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="Y">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Riluzole</Keyword><Keyword MajorTopicYN="N">diagnostic delay</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword><Keyword MajorTopicYN="N">survival</Keyword><Keyword MajorTopicYN="N">therapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>2</Hour><Minute>40</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36117390</ArticleId><ArticleId IdType="pmc">PMC9828202</ArticleId><ArticleId IdType="doi">10.1002/mus.27724</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole study group. N Engl J Med. 1994;330:585&#x2010;591.</Citation><ArticleIdList><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose&#x2010;ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis/Riluzole study group II. Lancet. 1996;347:1425&#x2010;1431.</Citation><ArticleIdList><ArticleId IdType="pubmed">8676624</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;3:CD001447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7055506</ArticleId><ArticleId IdType="pubmed">22419278</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews JA, Jackson CE, Heiman&#x2010;Patterson TD, Bettica P, Brooks BR, Pioro EP. Real&#x2010;world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21:509&#x2010;518.</Citation><ArticleIdList><ArticleId IdType="pubmed">32573277</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xe9;vesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ. 2010;340:b5087.</Citation><ArticleIdList><ArticleId IdType="pubmed">20228141</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulder MJHL, Jansen IGH, Goldhoorn R&#x2010;JB, et al. Time to endovascular treatment and outcome in acute ischemic stroke: MR CLEAN registry results. Circulation. 2018;138:232&#x2010;240.</Citation><ArticleIdList><ArticleId IdType="pubmed">29581124</ArticleId></ArticleIdList></Reference><Reference><Citation>Cone EB, Marchese M, Paciotti M, et al. Assessment of time&#x2010;to&#x2010;treatment initiation and survival in a cohort of patients with common cancers. JAMA Netw Open. 2020;3:e2030072.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7737088</ArticleId><ArticleId IdType="pubmed">33315115</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H, Kasarskis EJ, Simmons Z. Hastening the diagnosis of amyotrophic lateral sclerosis. Neurology. 2022;99:60&#x2010;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">35577578</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T, Al Khleifat A, Meurgey J&#x2010;H, et al. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose&#x2010;ranging study. Lancet Neurol. 2018;17:416&#x2010;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5899963</ArticleId><ArticleId IdType="pubmed">29525492</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jongh AD, van Eijk RPA, van den Berg LH. Evidence for a multimodal effect of riluzole in patients with ALS? J Neurol Neurosurg Psychiatry. 2019;90:1183&#x2010;1184.</Citation><ArticleIdList><ArticleId IdType="pubmed">30846539</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakore NJ, Lapin BR, Pioro EP. Pooled resource open&#x2010;access Als clinical trials consortium. Stage&#x2010;specific riluzole effect in amyotrophic lateral sclerosis: a retrospective study. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21:140&#x2010;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">31450993</ArticleId></ArticleIdList></Reference><Reference><Citation>Seibold H, Zeileis A, Hothorn T. Individual treatment effect prediction for amyotrophic lateral sclerosis patients. Stat Methods Med Res. 2018;27:3104&#x2010;3125.</Citation><ArticleIdList><ArticleId IdType="pubmed">29298618</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinchcliffe M, Smith A. Riluzole: real&#x2010;world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis. Degener Neurol Neuromuscul Dis. 2017;7:61&#x2010;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6053101</ArticleId><ArticleId IdType="pubmed">30050378</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J, Malerba SA, Beghi E, et al. Riluzole and other prognostic factors in ALS: a population&#x2010;based registry study in Italy. J Neurol. 2018;265:817&#x2010;827.</Citation><ArticleIdList><ArticleId IdType="pubmed">29404735</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CT&#x2010;C, Chiu Y&#x2010;W, Wang K&#x2010;C, et al. Riluzole and prognostic factors in amyotrophic lateral sclerosis long&#x2010;term and short&#x2010;term survival: a population&#x2010;based study of 1149 cases in Taiwan. J Epidemiol. 2013;23:35&#x2010;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3700231</ArticleId><ArticleId IdType="pubmed">23117224</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Liu X, Tang L, Zhang N, Fan D. Long&#x2010;term use of riluzole could improve the prognosis of sporadic amyotrophic lateral sclerosis patients: a real&#x2010;world cohort study in China. Front Aging Neurosci. 2016;8:246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5075535</ArticleId><ArticleId IdType="pubmed">27822184</ArticleId></ArticleIdList></Reference><Reference><Citation>Cetin H, Rath J, F&#xfc;zi J, et al. Epidemiology of amyotrophic lateral sclerosis and effect of riluzole on disease course. Neuroepidemiology. 2015;44:6&#x2010;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">25571962</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence&#x2010;based review): report of the quality standards Subcommittee of the American Academy of neurology. Neurology. 2009;73:1227&#x2010;1233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2764728</ArticleId><ArticleId IdType="pubmed">19822873</ArticleId></ArticleIdList></Reference><Reference><Citation>Atassi N, Berry J, Shui A, et al. The PRO&#x2010;ACT database: design, initial analyses, and predictive features. Neurology. 2014;83:1719&#x2010;1725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4239834</ArticleId><ArticleId IdType="pubmed">25298304</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS&#x2010;R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS study group (phase III). J Neurol Sci. 1999;169:13&#x2010;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159:179&#x2010;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">9872837</ArticleId></ArticleIdList></Reference><Reference><Citation>van Buuren S, Groothuis&#x2010;Oudshoorn K. mice: Multivariate imputation by chained equations in R. J Stat Softw 2011;45:1&#x2010;67.</Citation></Reference><Reference><Citation>Wood AM, White IR, Royston P. How should variable selection be performed with multiply imputed data? Stat Med. 2008;27:3227&#x2010;3246.</Citation><ArticleIdList><ArticleId IdType="pubmed">18203127</ArticleId></ArticleIdList></Reference><Reference><Citation>Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515&#x2010;526.</Citation></Reference><Reference><Citation>Austin PC. The use of propensity score methods with survival or time&#x2010;to&#x2010;event outcomes: reporting measures of effect similar to those used in randomized experiments: propensity scores and survival analysis. Stat Med. 2014;33:1242&#x2010;1258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4285179</ArticleId><ArticleId IdType="pubmed">24122911</ArticleId></ArticleIdList></Reference><Reference><Citation>Granger E, Sergeant JC, Lunt M. Avoiding pitfalls when combining multiple imputation and propensity scores. Stat Med. 2019;38:5120&#x2010;5132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6856837</ArticleId><ArticleId IdType="pubmed">31512265</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakore NJ, Lapin BR, Pioro EP, Aboussouan LS. Variation in noninvasive ventilation use in amyotrophic lateral sclerosis. Neurology. 2019;93:e306&#x2010;e316.</Citation><ArticleIdList><ArticleId IdType="pubmed">31182506</ArticleId></ArticleIdList></Reference><Reference><Citation>Geronimo A, Albertson RM, Noto J, Simmons Z. Ten years of riluzole use in a tertiary ALS clinic. Muscle Nerve. 2022;65:659&#x2010;666.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9275511</ArticleId><ArticleId IdType="pubmed">35353910</ArticleId></ArticleIdList></Reference><Reference><Citation>
Therneau T
(2022). 
A Package for Survival Analysis in R. R package version 3.4&#x2010;0. https://CRAN.R-project.org/package=survival.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>